Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Anal Bioanal Chem ; 406(18): 4337-43, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24788891

ABSTRACT

The most widely used method for the biochemical screening of oligosaccharidoses is the analysis of the urinary oligosaccharide pattern by thin-layer chromatography on silica gel plates. However, this method is not always sensitive enough, and it is extremely time-consuming and laborious. In this work, the analysis of the urine oligosaccharide pattern was standardized for the first time by using capillary electrophoresis with laser-induced fluorescence (CE-LIF) detection (Beckman P/ACE MDQ) with a 488-nm argon ion laser module. All of the analyses were conducted using the Carbohydrate Labeling and Analysis Kit (Beckman-Coulter), which derivatizes samples with 8-aminopyrene-1,3,6-trisulfonate. Urine samples from 40 control subjects (age range, 1 week to 16 years) and from ten patients diagnosed with eight different lysosomal diseases (six of them included in the Educational Oligosaccharide Kit from ERNDIM EQA schemes) were analyzed. Two oligosaccharide excretion patterns were established in our control population according to age (younger or older than 1 year of age). Abnormal peaks with slower migration times than the tetrasaccharide position were observed for fucosidosis, α-mannosidosis, GM1 gangliosidosis, GM2 gangliosidosis variant 0, Pompe disease, and glycogen storage disease type 3. In conclusion, the first CE-LIF method to screen for oligosaccharidoses and related diseases, which also present oligosacchariduria, has been standardized. In all of the cases, the urine oligosaccharide analysis was strongly informative and showed abnormal patterns that were not present in any of the urine samples from the control subjects. Only urine from patients with aspartylglucosaminuria and Schindler disease displayed normal results.


Subject(s)
Electrophoresis, Capillary/methods , Lysosomal Storage Diseases/urine , Oligosaccharides/urine , Adolescent , Aspartylglucosaminuria/urine , Case-Control Studies , Child , Child, Preschool , Electrophoresis, Capillary/instrumentation , Electrophoresis, Capillary/standards , Fucosidosis/urine , Glycogen Storage Disease Type II/urine , Humans , Infant , Infant, Newborn , Lasers , Lysosomal Storage Diseases/diagnosis , Neuroaxonal Dystrophies/urine , Sandhoff Disease/urine , alpha-N-Acetylgalactosaminidase/deficiency , alpha-N-Acetylgalactosaminidase/urine
2.
Clin Chem ; 59(9): 1357-68, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23676310

ABSTRACT

BACKGROUND: There are 45 known genetic diseases that impair the lysosomal degradation of macromolecules. The loss of a single lysosomal hydrolase leads to the accumulation of its undegraded substrates in tissues and increases of related glycoconjugates in urine, some of which can be detected by screening of free oligosaccharides (FOS) in urine. Traditional 1-dimensional TLC for urine oligosaccharide analysis has limited analytical specificity and sensitivity. We developed fast and robust urinary FOS and glycoaminoacid analyses by MALDI-time-of-flight/time-of-flight (MALDI-TOF/TOF) mass spectrometry for the diagnosis of oligosaccharidoses and other lysosomal storage diseases. METHODS: The FOS in urine equivalent to 0.09 mg creatinine were purified through sequential passage over a Sep-Pak C18 column and a carbograph column and were then permethylated. MALDI-TOF/TOF was used to analyze the permethylated FOS. We studied urine samples from individuals in 7 different age groups ranging from 0-1 months to ≥ 17 years as well as urine from known patients with different lysosomal storage diseases. RESULTS: We identified diagnostic urinary FOS patterns for α-mannosidosis, galactosialidosis, mucolipidosis type II/III, sialidosis, α-fucosidosis, aspartylglucosaminuria (AGU), Pompe disease, Gaucher disease, and GM1 and GM2 gangliosidosis. Interestingly, the increase in urinary FOS characteristic of lysosomal storage diseases relative to normal FOS appeared to correlate with the disease severity. CONCLUSIONS: The analysis of urinary FOS by MALDI-TOF/TOF is a powerful tool for first-tier screening of oligosaccharidoses and lysosomal storage diseases.


Subject(s)
Lysosomal Storage Diseases/diagnosis , Lysosomal Storage Diseases/urine , Oligosaccharides/urine , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Adolescent , Aspartylglucosaminuria/diagnosis , Aspartylglucosaminuria/urine , Child , Child, Preschool , Female , Fucosidosis/diagnosis , Fucosidosis/urine , Gangliosidoses, GM2/diagnosis , Gangliosidoses, GM2/urine , Gangliosidosis, GM1/diagnosis , Gangliosidosis, GM1/urine , Gaucher Disease/diagnosis , Gaucher Disease/urine , Glycogen Storage Disease Type II/diagnosis , Glycogen Storage Disease Type II/urine , Humans , Infant , Infant, Newborn , Male , Mannosidase Deficiency Diseases/diagnosis , Mannosidase Deficiency Diseases/urine , Mucolipidoses/diagnosis , Mucolipidoses/urine
SELECTION OF CITATIONS
SEARCH DETAIL